News · The Mohi Lab
Awards, grants,
papers, press.
25 entries spanning 2001–2025, drawn from UVA Medicine in Motion, the BMG department, patient-advocacy press, and the lab’s own publication record. Each card links out to the original. Subscribe via /rss.xml.
2025
9 entries- 6Dec · 2025Press
ASH 2025: Nuvisertib (TP-3654) combination data, plus Enzomenib presentations
Sumitomo Pharma America presents updated Phase 1/2 investigational data on Nuvisertib (TP-3654) in combination with momelotinib for relapsed/refractory myelofibrosis with anemia. Early signals: well-tolerated combination, spleen and symptom improvements. The drug is the same PIM1 inhibitor whose preclinical efficacy the lab established (Dutta et al., Leukemia 2022).
Sumitomo Pharma AmericaASH 2025 · Phase 1/2
Read ↗
- 4Sep · 2025Press
Research in Motion video — Dr. Golam Mohi
BMG mirror of the UVA School of Medicine video feature on the lab's work, framed by the PI's signature line on the goal: find new therapeutic targets for leukemia.
UVA BMG
Read ↗
- 2Sep · 2025Press
Research in Motion: Golam Mohi, PhD
UVA SOM's video feature series. The lab's working philosophy in two sentences and the throughline behind every paper, grant, and trial.
UVA Medicine in Motion
Read ↗
- 30Jul · 2025Press
EMA grants Orphan Drug Designation to Nuvisertib (TP-3654) for myelofibrosis
European Medicines Agency Orphan Drug Designation for Nuvisertib, the oral PIM1 kinase inhibitor whose preclinical work originated in the lab. Brings EU regulatory acceleration to the same compound covered by the lab's 2022 Leukemia paper.
Sumitomo Pharma AmericaEMA · Orphan Drug
Read ↗
- 12Jun · 2025Press
FDA Fast Track Designation for Nuvisertib (TP-3654) in myelofibrosis
FDA Fast Track for the oral PIM1 inhibitor Nuvisertib (TP-3654), the compound whose preclinical efficacy the lab established. Brings expedited regulatory review to the trial program (NCT04176198) where UVA Cancer Center is a major site.
Sumitomo Pharma AmericaFDA · Fast Track
Read ↗
- 12Jun · 2025Press
EHA 2025: Phase 1/2 Nuvisertib monotherapy data in relapsed/refractory MF
Updated Phase 1/2 data presented at the European Hematology Association Congress: Nuvisertib monotherapy well-tolerated with no DLTs. Evaluable patients showed ≥25% spleen volume reduction (22.2%), ≥50% TSS reduction (44.4%), and bone marrow fibrosis improvement (42.9%).
EHA 2025 CongressEHA 2025
Read ↗
- 7Feb · 2025Grant
$2.4M R01 to study JAK2V617F-driven MPN progression
BMG mirror of the Medicine in Motion announcement. The R01 funds investigation of newly identified targets in MPN development and progression, toward therapies that move past current JAK inhibitors.
UVA BMG$2.4M · R01
Read ↗
- 4Feb · 2025Grant
Awarded $2.4 Million to study myeloproliferative neoplasms
NIH R01 titled "Molecular Basis for Progression of Myeloproliferative Neoplasms Induced by JAK2V617F." The award supports work on new therapeutic targets where current JAK2 inhibitors manage symptoms but do not achieve remission or reduce fibrosis.
UVA Medicine in Motion$2.4M · R01
Read ↗
- 10Feb · 2025Press
UVA researcher receives $2.4M for MPN progression study
Patient-advocacy press picks up the R01 award announcement, framing the lab's work for the MPN patient community.
PV ReporterPatient-advocacy press
Read ↗
2024
1 entry2023
4 entries- 9Dec · 2023Publication
ASH 2023: Genetic deletion or pharmacologic inhibition of PTPN11 in MPN
Lab presentation at ASH 2023 Annual Meeting: PTPN11 inhibition impedes MPN development and progression in JAK2V617F and MPLW515L mouse models. Connects the postdoc-era PTPN11/Shp2 work to the lab's current MPN program.
ASH 2023 Annual MeetingASH 2023 · Abstract
Read ↗
- 18Jul · 2023Grant
Two NIH grants for $2.8M — U2AF1 (R01) and IL-1 (R21)
Combined NIH/NHLBI R01 on the molecular basis for myelodysplasia induced by U2AF1 mutations, plus an NIH/NCI R21 testing pharmacologic IL-1 inhibition in myelofibrosis. Named collaborators: Chongzhi Zang and Gloria Sheynkman at UVA.
UVA Medicine in Motion$2.8M · R01 + R21
Read ↗
- 26May · 2023Award
Dr. Mohi to lead the new Hematologic Malignancies Translational Research Team
Co-leadership of the UVA Cancer Center's Hematologic Malignancies TRT, established to advance the translation of blood cancer research toward clinical trials. UVA Cancer Center is a major site for the TP-3654 (Nuvisertib) trial NCT04176198.
UVA BMGTRT Co-Leader
Read ↗
- 30Nov · 2023Publication
SRSF2 mutation modifies JAK2V617F MPN
Yang, Abbas et al. show how the splicing-factor mutation SRSF2 reduces erythrocytosis but compromises hematopoietic progenitor function in JAK2V617F-driven MPN, connecting the lab's MPN and MDS programs.
Blood Cancer JournalBlood Cancer J.
Read ↗
2022
3 entries- 10Nov · 2022Publication
Research points to a new treatment approach for bone marrow cancer
Press release for the lab's Nature Communications paper showing IL-1 signaling drives clonal expansion and bone marrow fibrosis in JAK2V617F MPN. Genetic and pharmacologic IL-1 inhibition ameliorates myelofibrosis in murine models.
UVA BMGNat. Commun. · 2022
Read ↗
- 15May · 2022Press
FDA Orphan Drug Designation for Nuvisertib (TP-3654) in myelofibrosis
First major regulatory designation for the PIM1 inhibitor that the lab demonstrated efficacious in murine MPN. Confirms the rare-disease pathway for the compound.
Sumitomo PharmaFDA · Orphan Drug
Read ↗
- 1Mar · 2022Publication
Genetic ablation of PIM1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis
Translational basis for the multicenter Phase 1/2 trial NCT04176198 (TP-3654 / Nuvisertib). Murine work showed that genetic Pim1 ablation prevents myelofibrosis and that the small-molecule inhibitor reduces leukocytosis, splenomegaly, and bone marrow fibrosis.
LeukemiaLeukemia · 2022
Read ↗
2021
2 entries- 15Aug · 2021Publication
CDK6 is a therapeutic target in myelofibrosis
CDK4/6 inhibitor Palbociclib reduces leukocytosis, splenomegaly, and blocks fibrosis in JAK2V617F mouse models. Combined with Ruxolitinib, the combination normalizes blood counts and abrogates marrow fibrosis.
Cancer ResearchCancer Research
Read ↗
- 1Aug · 2021Publication
U2AF1 is required for survival and function of hematopoietic stem/progenitor cells
Conditional U2AF1 deletion produces pancytopenia, HSPC loss, bone marrow failure, and early lethality. Anchor MDS paper for the lab's splicing-factor program; supports the active R01 NHLBI award.
LeukemiaLeukemia · 2021
Read ↗
2020
1 entry2017
1 entry2013
1 entry2012
1 entry2005
1 entry2001
1 entryStay current